Ng O, Watts E, Bull C A, Morris R, Acheson A, Banerjea A
University of Nottingham , UK.
Queens Medical Centre , Nottingham , UK.
Ann R Coll Surg Engl. 2016 Mar;98(3):216-21. doi: 10.1308/rcsann.2016.0085.
The prevalence of colorectal cancer is increasing in the elderly. We examined the treatment and outcomes in our institution of patients aged over 85 years with proven colorectal adenocarcinoma.
One hundred and five patients were identified and stratified by treatment received: curative surgery (CS), other treatments (OT) or best supportive care (BSC). Data on demographics, staging, treatment and survival was collected and analysed.
Forty two patients received CS, 36 OT and 27 BSC. While the treated groups (CS and OT) were similar in terms of age (p=0.35) and staging (p=0.16), BSC patients were significantly older and had higher stage disease (p<0.01). Survival was significantly poorer among BSC patients, at a mean of 9.7 months (95% confidence interval [CI] 4.7-14.7) versus 41.6 months (95% CI 32.5-50.7) and OT 27.3 months (95% CI 20.4-34.1) for the CS and OT groups (p<0.001). There was no significant survival difference between CS and OT groups within 2 years of treatment (p=0.12). Thereafter, OT patients had a very similar 5-year survival to that of the BSC group, at 13% versus 43% in CS patients (p<0.001).
These data suggest that, up to 2 years following treatment, the risks of resectional surgery for colorectal cancer may neutralise any benefit. However, those that survive beyond this period show improvements. The challenge of improving patient selection is most acute in the growing ageing population, and highlights the current focus on presenting all treatment options to 'a reasonable patient'.
老年人大肠癌的患病率正在上升。我们研究了我院85岁以上经证实患有大肠腺癌患者的治疗情况及预后。
共确定了105例患者,并根据接受的治疗进行分层:根治性手术(CS)、其他治疗(OT)或最佳支持治疗(BSC)。收集并分析了患者的人口统计学、分期、治疗及生存数据。
42例患者接受了CS,36例接受了OT,27例接受了BSC。治疗组(CS和OT)在年龄(p=0.35)和分期(p=0.16)方面相似,但接受BSC的患者年龄显著更大,疾病分期更高(p<0.01)。BSC组患者的生存情况明显较差,平均生存期为9.7个月(95%置信区间[CI]4.7 - 14.7),而CS组为41.6个月(95%CI 32.5 - 50.7),OT组为27.3个月(95%CI 20.4 - 34.1)(p<0.001)。治疗后2年内,CS组和OT组之间的生存差异无统计学意义(p=0.12)。此后,OT组患者的5年生存率与BSC组非常相似,分别为13%和43%,而CS组为43%(p<0.001)。
这些数据表明,在治疗后的2年内,大肠癌切除手术的风险可能抵消任何益处。然而,那些生存期超过这一时期的患者情况有所改善。在不断增长的老年人群体中,改善患者选择的挑战最为严峻,这凸显了当前将所有治疗方案呈现给“理性患者”的重点。